A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients
NCT03389815
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
48
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Tumor, Non-small Cell Lung Cancer
Interventions
DRUG:
WX-0593 Tablets
Sponsor
Qilu Pharmaceutical Co., Ltd.